HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sharov, V. G. Articles by Javadov, S. A. Search for Related Content PubMed PubMed Citation Articles by Sharov, V. G. Articles by Javadov, S. A.

The Journal of Thoracic and Cardiovascular Surgery, Vol 94, 749-761, Copyright © 1987 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Protection of ischemic myocardium by exogenous phosphocreatine. I. Morphologic and phosphorus 31-nuclear magnetic resonance studies

VG Sharov, VA Saks, VV Kupriyanov, VL Lakomkin, VI Kapelko, AYa Steinschneider and SA Javadov
USSR Cardiology Research Center, Moscow.

A phosphorus 31-nuclear magnetic resonance method was used to study the effect of exogenous phosphocreatine on the isolated perfused rat heart. The hearts were chemically arrested by St. Thomas' Hospital solution and made totally ischemic for 35 minutes at 37 degrees C. In the presence of phosphocreatine, 10 mmol/L, during ischemia, almost complete recovery of heart function and phosphocreatine content and 61% recovery of adenosine triphosphate content were observed after 30 minutes of postischemic reperfusion; in the control experiments without phosphocreatine, contractile function, intracellular phosphocreatine, and adenosine triphosphate contents were restored to 33%, 43%, and 26% of their normal values, respectively. Ultrastructural studies with a lanthanum tracer method showed remarkable protection of sarcolemma against ischemic injury by exogenous phosphocreatine at the level of the glycocalyx.

This article has been cited by other articles:

				L. G. Menezes, C. Sobreira, L. Neder, A. L. Rodrigues-Junior, and J. A. Baddini Martinez Creatine supplementation attenuates corticosteroid-induced muscle wasting and impairment of exercise performance in rats J Appl Physiol, February 1, 2007; 102(2): 698 - 703. [Abstract] [Full Text] [PDF]

				A. M. Persky and G. A. Brazeau Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate Pharmacol. Rev., May 11, 2001; (2001) 1. [Abstract] [Full Text]

				D. J. Chambers, K. Haire, N. Morley, L. Fairbanks, E. Strumia, C. P. Young, and G. E. Venn St. Thomas' Hospital Cardioplegia: Enhanced Protection With Exogenous Creatine Phosphate Ann. Thorac. Surg., January 1, 1996; 61(1): 67 - 75. [Abstract] [Full Text]

				P. Mastroroberto, M. Chello, S. Zofrea, E. Bevacqua, and A. R. Marchese Cardioprotective Effects of Phosphocreatine in Vascular Surgery Vascular and Endovascular Surgery, July 1, 1995; 29(4): 255 - 260. [Abstract] [PDF]

				A. M. Persky and G. A. Brazeau Clinical Pharmacology of the Dietary Supplement Creatine Monohydrate Pharmacol. Rev., June 1, 2001; 53(2): 161 - 176. [Abstract] [Full Text] [PDF]